Status:
RECRUITING
A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries
Lead Sponsor:
FrontAce Scientific Co., Ltd
Conditions:
Peripheral Arterial Disease
Stenosis
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
This is a prospective, multi-center, randomized trial designed to investigate the efficacy and safety of Sperstent® peripheral spot stent system versus Everflex® self-expanding peripheral stent system...
Eligibility Criteria
Inclusion
- Age 18-85 years old, male or female;
- The target lesion is located in the superficial femoral artery or the proximal popliteal artery;
- Peripheral arterial stenosis or occlusive disease with symptoms consistent with the Rutherford classification 2 to 5;
- Estimated life expectancy \>1 year;
- Subject has been informed of and understands the nature of the study and provides signed informed consent to participate in the study.
- Angiographic
- Stenosis rate ≥70% under DSA by visual estimate, or 100% occluded lesion with a total lesion length less than 150mm (by visual estimate);
- Reference vessel diameter is between 3 mm and 7.5 mm, 50mm≤Total cumulative length of target lesions≤250mm; (In the case of bilimb lesions, a single target lesion with one limb meeting the protocol criteria is selected by the investigator; More than 2cm between lesions are considered as 2 lesions);
- After PTA treatment by DCB, there exists residual lesions, such as the target lesion has over 30% residual DS and/or presence of at least one post-PTA dissection (Type A-F) (by visual estimate);
- Patients with unobstructed inflow tract or successfully treated, visual residual stenosis ≤50%;
- Angiography showed at least one outflow tract was unobstructed at the distal end (Stenosis degree ≤70% before intervention).
Exclusion
- Target vessel had undergone open surgery such as bypass surgery or the target lesion is in-stent restenosis;
- Patients with serum creatinine \>2.5mg/dl during screening or undergoing long-term hemodialysis or peritoneal dialysis;
- Severe coagulation disorder;
- Patients with major vascular-related diseases, including acute lower extremity ischemia, active disseminated intravascular coagulation, thromboangiitis obliterans, deep vein thrombosis, and aneurysms of therapeutic lateral vessels (deep femur, superficial femur, or popliteal artery);
- A history of major organ failure or other serious illness (including severe coronary heart disease, severe cardiac insufficiency, severe neurosis, or mental illness); Have received or plan organ transplantation, severe gastrointestinal bleeding);
- Myocardial infarction or symptomatic stroke occurred within 3 months prior to enrollment;
- Thrombolysis of target vessel within 72 hours before surgery, did not completely dissolve the thrombus;
- Systemic infection or uncontrolled infection within the target limb;
- Known allergy to contrast agents, nickel or titanium (Nitinol), heparin, aspirin, clopidogrel, anesthetics;
- Women who are pregnant or breast-feeding, or women of childbearing age who have family plans within 1 year;
- Patients who are planning to have major lower limb amputations on the target side of the lesion;
- Endovascular or surgical procedures are performed on the target limb within 30 days before or 30 days after surgery;
- Participating in clinical trials of other medical devices or drugs;
- The investigator considers the patient is not suitable for participation in the clinical trial.
- Angiographic
Key Trial Info
Start Date :
June 4 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT06539689
Start Date
June 4 2024
End Date
December 31 2026
Last Update
August 6 2024
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
2
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
3
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
4
First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China